Governance evolution at BIOASTER,

microbiology technology institute

Nathalie GARÇON Chief Scientific Officer and Pascale BOISSEL Chief Financial Officer have been respectively named chief executive officer and deputy chief executive officer.

Lyon, April 20th, 2015: BIOASTER microbiology technology institute announced that its board of directors has decided during his 2nd of April plenary session, to evolve BIOASTER governance, appointing Nathalie GARÇON, currently BIOASTER chief scientific officer, to the position of chief executive officer of the Foundation. She keeps her responsibilities as chief scientific officer.

Pascale BOISSEL has been appointed deputy chief executive officer. She keeps her responsibilities as chief financial and administration officer, a position she has held since the legal establishment of the foundation in April 2012.

The experience acquired by Nathalie GARÇON and Pascale BOISSEL prior to their arrival at BIOASTER, as well as the remarkable structuration work they have already accomplished with the teams, put them naturally at BIOASTER helm, at a time where the foundation is accelerating its development, within and outside of France.

Philippe ARCHINARD, President of BIOASTER commented: "These appointments were motivated by the Board of Directors wish to recognise the quality of the work carried out by the teams, to strengthen the new organisation set up in October 2014, to confirm the agility of the operational decision-making as well as to re-enforce the independent nature of the foundation. Ms GARÇON and Ms BOISSEL have been key drivers at BIOASTER .Our purpose is to establish a governance combining scientific and financial management, which are two key elements for the sustainability of the BIOASTER model".

Brief Biography - Nathalie GARÇON

Before joining BIOASTER in July 2014 as chief scientific officer, Nathalie GARÇON held the position of Vice President, Head of Global adjuvant and Technologies Innovation Centre at GlaxoSmithKline (GSK) Vaccines.

Nathalie GARÇON is a biological pharmacist, Doctor in pharmaceutical sciences and has a PhD in immune-toxicology, immune-pharmacology. She began her career in 1986 in academic research - at London's Royal Free Hospital and then at Baylor College of Medicine in Houston, Texas.

From 1990 to 2014 at GSK, Nathalie GARÇON devoted most of her career to the field of adjuvants in vaccines, from discovery to registration and commercialisation. In 2014, she was awarded the Stanley Plotkin award for life time achievements and contributions in the field of vaccines and vaccine technologies.

Nathalie GARÇON has authored over 60 papers and chapters in scientific journals and books and is also the inventor of numerous patents.

https://www.linkedin.com/pub/nathalie-garcon/17/542/890

Brief Biography - Pascale BOISSEL

Pascale BOISSEL began her career in 1989 and spent most of it in corporate accounting and business control for large listed groups with a broad international exposure. She notably served as Vice President within Lafarge group Finance Team.

Before joining BIOASTER, from 2009 to 2012, Pascale BOISSEL was Chief Financial Officer of QIAGEN MARSEILLE (formerly IPSOGEN), where she was instrumental in the reorganisation of US based operations and coordinated a major capital increase fund raising. She actively supported the acquisition of the Company by the Qiagen Group in the summer of 2011, which resulted in a very positive return for all shareholders.

A HEC graduate, Pascale Boissel, is also a Chartered Accountant.

https://www.linkedin.com/pub/pascale-boissel/39/9a9/34

ABOUT BIOASTER

BIOASTER is a technology institute that leads research programs in four major application fields in health-related microbiology and infectious diseases: vaccines, antimicrobials, diagnosis and microbiota. BIOASTER implements transdisciplinary R&D programs that bring together academics, small and medium-sized enterprises and industrials around thematic and technology units. Each project is undertaken by a team of high-level scientists and engineers that benefits from state-of-the-art equipment, technological infrastructures and academic research excellence. Teams are led by managers who are wellversed in the industrial standards, as well as from partnerships carefully developed for conducting breakthrough innovations. BIOASTER, an independent non-profit organization, is one of eight French TRIs (Technology Research Institutes). It was created in 2012 at the initiative of Lyonbiopôle and the Institut Pasteur in Paris. It was founded by CNRS, INSERM, the CEA, Mérieux Institute, Danone Research and Sanofi Pasteur and is supported by 40 SMEs in the Lyon and Paris regions as well as the French government, through the Investments for the future program for the Grand Lyon la métropole and the Rhône-Alpes region.
Benefiting from two different locations in Lyon and Paris, BIOASTER has a staff of an hundred people, including more than 70 scientists and engineers, from 16 different nationalities.

Contacts Presse: